Cyclosporin A was approved for organ transplants in the early 1980s, yet scientists did not realize it was a molecular glue until the early 1990s.
That decade-long gap frames a broader case: molecular-glue degraders (MGDs) are shifting from an accidental discovery process to a screenable drug-design platform, as improved understanding of protein degrons lets researchers hunt for previously undruggable targets. Two Natural Capital, which does not disclose a position in the companies discussed, argues that platform developers such as Monte Rosa Therapeutics (GLUE) and Triana Biomedicines stand to benefit from this shift. The report points to RevMed's newly approved Daraxonrasib as evidence the underlying molecular-glue mechanism can already produce commercially significant medicines.
Ticker: GLUE (Monte Rosa Therapeutics)
Research Firm: Two Natural Capital
Report URL: https://www.twonaturalcap.com/p/molecular-glue-degraders-moving-from?ref=shortreport.fyi
Position Disclosure: Not disclosed in the source report (no short or long position stated).
Thesis
Two Natural Capital's report argues that advances in degron biology and protein-surface screening are turning molecular-glue degraders from an accidental discovery story into a rationally designable drug platform, positioning companies including Monte Rosa Therapeutics (GLUE) and Triana Biomedicines to benefit.
- Undruggable Target Expansion: Molecular glues and PROTACs are already reaching targets conventional small molecules could not, including Kymera's KT-621 (STAT6), RevMed's FDA-approved Daraxonrasib (RAS(ON) via a Cyp(A) tri-complex), Arvinas' BCL6, Monte Rosa's GSPT1, and Foghorn's ARID1B programs.
- Oral Pill Advantage: The report frames oral degraders as a commercial edge over injectable biologics, citing Kymera's KT-621 as potential "Dupixent-like" oral efficacy, Lilly's push into oral GLP-1s, investor interest in Protagonist's oral IL-23 inhibitor, and Otezla's commercial performance in psoriasis "despite subpar efficacy."
- Resistance-Proof Degradation: Degraders may sidestep the resistance mutations and off-target toxicity that limit kinase inhibitors, with Triana's ALK-positive NSCLC work cited alongside GSK's roughly $10 billion acquisition of Nuvalent as evidence of demand for brain-penetrant ALK therapies.
- Parkinson's Degrader Bet: Because Biogen and Denali's kinase-inhibiting LRRK approaches "have not shown much promise" per the author, the report argues full protein degradation could succeed where inhibition has not in Parkinson's disease.
- Accidental Discovery History: MGDs have historically been found by accident rather than designed: Cyclosporin A was approved for transplants in the early 1980s but not identified as a molecular glue until the early 1990s, and thalidomide was approved for multiple myeloma in 2006 with its cereblon-binding mechanism not understood until 2014.
- Proteome-Wide Degron Screen: Monte Rosa researchers screened the structural proteome for surface-exposed "G-loop"-like degron motifs and found them distributed across more than 250 domain types and nearly 100 target classes, "many new to this modality and currently perceived as inaccessible to small-molecule ligands."
- Surface-Similarity Targeting: Even proteins lacking an obvious degron may be reachable: VAV1 had no clear surface-exposed G-loop but shared a molecular surface with GSPT1 and formed a tri-complex with cereblon and a molecular glue in Monte Rosa's work.
- Platform Company Bet: The author concludes that evolving degron science and this early screening work make Monte Rosa and Triana Biomedicines viable platform investments, though this remains the author's inference rather than a proven commercial outcome.
Catalysts
- Monte Rosa platform validation: Further clinical or preclinical validation of Monte Rosa's degron- and surface-screening MGD platform (no date specified) would test whether the screening approach translates into clinical candidates.
- Triana ALK program progress: Clinical progress in Triana Biomedicines' ALK-positive NSCLC programs (no date specified) would support the platform's oncology thesis if readouts are positive.
- Daraxonrasib uptake and modality validation: Continued regulatory or commercial validation of molecular-glue drugs, including RevMed's Daraxonrasib, estimated near $10 billion in peak sales, would reinforce the modality's commercial case.
- Undruggable-target expansion evidence: Additional evidence that degraders can reach previously undruggable targets in oncology, immunology, or neurodegenerative disease (no date specified) would broaden the target universe the thesis depends on.
Company Response
The report does not indicate that Monte Rosa Therapeutics, Triana Biomedicines, RevMed, or any other company discussed was asked for comment. No company responses are recorded in the source material.
Notable Details
- Daraxonrasib's Cyp(A)-RAS(ON) tri-complex produced roughly double the progression-free survival of standard care in metastatic pancreatic ductal adenocarcinoma patients.
- The author frames Daraxonrasib's commercial potential at approximately $10 billion in peak sales, without citing a source for the estimate.
- A lenalidomide analogue was found to degrade CK1α and GSPT1, proteins with no obvious structural resemblance to its known IKZF1/IKZF3 targets, a link later explained by a shared "G-loop" degron.
- PROTACs can become less effective at higher doses because the bifunctional molecules can "crowd themselves out," binding the target protein and E3 ligase separately instead of forming the ternary complex needed for degradation.
"These degraders are useful because they alter the E3 ligase/POI structure; a study of those structures beforehand is largely only going to reveal that the E3 ligase/POI structures don't lend themselves to favorable PPIs, which is exactly why the molecular glue is being designed in the first place!"
The author uses this passage to explain why rationally designing molecular-glue degraders has historically been so difficult.
FAQs
What is GLUE and why does the Two Natural Capital report focus on it?
Monte Rosa Therapeutics trades under the ticker GLUE and is cited in the report as a molecular-glue-degrader platform company. Its researchers screened the structural proteome for degron-like motifs, identifying more than 250 domain types and nearly 100 target classes that could potentially be drugged with molecular glues.
What does Monte Rosa Therapeutics do in molecular-glue-degrader research?
Monte Rosa Therapeutics develops molecular-glue degraders, small molecules that induce a cell's own E3 ligase machinery to destroy target proteins. The report cites its work on GSPT1 in castration-resistant prostate cancer and a published screen for surface-exposed degron motifs across the structural proteome.
What does Two Natural Capital argue in its molecular-glue degrader report?
Two Natural Capital argues that molecular-glue degraders are becoming more investable because improved understanding of degron biology and protein surfaces may let researchers rationally design MGDs against targets once considered undruggable. It names Monte Rosa Therapeutics and Triana Biomedicines as platform companies positioned to benefit.
What is a molecular glue degrader (MGD) and how does it differ from a PROTAC?
An MGD is a single small molecule that brings a target protein and an E3 ligase together to trigger degradation, while a PROTAC links two small-molecule components with a chemical linker. The report notes MGDs generally follow conventional "rule of 5" drug design and avoid the PROTAC "hook effect," in which higher doses can reduce degradation because the two ends of the molecule bind their targets separately instead of forming a three-way complex.
What is Daraxonrasib and why is it central to the report's thesis?
Daraxonrasib is RevMed's FDA-approved drug for metastatic pancreatic cancer that binds Cyp(A) and forms a tri-complex with RAS(ON), a long-sought cancer target. The report cites data showing it roughly doubled progression-free survival versus standard care and estimates its peak sales at approximately $10 billion, using it as evidence that molecular-glue mechanisms can already produce commercially significant drugs.
What is Triana Biomedicines and what is its role in the thesis?
Triana Biomedicines is a molecular-glue-degrader platform company cited in the report for its work in ALK-positive non-small-cell lung cancer. The author points to GSK's roughly $10 billion acquisition of Nuvalent, developer of the non-degrader ALK drug neladalkib, as evidence of commercial demand for brain-penetrant ALK-positive therapies that Triana's degrader approach might also address.
Why did it take so long to understand how thalidomide and cyclosporin A work as molecular glues?
Cyclosporin A was approved for organ transplants in the early 1980s but was not identified as a molecular glue until the early 1990s, and thalidomide was approved for multiple myeloma in 2006 with its cereblon-binding mechanism not adequately understood until 2014. The report uses both cases to illustrate that molecular glues have historically been found by accident, the discovery problem newer degron-screening methods aim to solve.
Does the report disclose a financial position in the companies it discusses?
No short or long position is stated in the source report from Two Natural Capital regarding Monte Rosa Therapeutics, Triana Biomedicines, or the other companies named. The report reads as a thematic research note on molecular-glue degraders rather than a disclosed trading position.
Disclaimer: This summary is not primary research and does not constitute investment advice. It is a brief overview of a detailed equity research report authored by the firm, organization, or source referenced in this article or at https://www.twonaturalcap.com/p/molecular-glue-degraders-moving-from, which contains extensive evidence, regulatory filings, and analysis; readers are encouraged to review the full report there for a comprehensive understanding. The content provided in this publication is not authored or originated by us — we act solely as a distributor and do not endorse, verify, or take responsibility for the accuracy, completeness, or reliability of the information presented. This publication is for informational purposes only and should not be construed as legal, business, investment, or tax advice. Always conduct independent due diligence and consult qualified professionals before making any decisions based on the information contained herein. We disclaim all liability for any loss or damage arising from reliance on third-party content, and the views expressed are solely those of the respective source and do not necessarily reflect our own.